Click Here to view online
|
 |
An e-mail newsletter for retina specialists from the
Publishers of Retinal Physician |
Sunday, September 21, 2014 |
|
|
 |
|
 |
| Phase III Trials Initiated for Lampalizumab for Treatment of GA
|
|
|
|
Genentech
and Roche have announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug
for the treatment of geographic atrophy, the advanced form of AMD. The phase III study will evaluate the safety and efficacy of lampalizumab and its
potential to slow the progression of GA. The studies will also further explore if people with a specific genetic biomarker, a mutation in complement factor
I, may benefit more from lampalizumab treatment. The trial design was released at the 14th EURETINA Congress 2014 in London. More information can be found at http://www.medicalnewstoday.com/releases/282550.php.
|
|
|
|
|
| INTREPID Study of Oraya Therapy Continues to Show Favorable Safety Profile |
|
|
|
Oraya Therapeutics, Inc. has
announced that full results of three-year safety data from the INTREPID study of Oraya Therapy for wet AMD further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated
with Oraya Therapy compared with those receiving anti-VEGF injections alone. Oraya Therapy uses low-energy, highly targeted X-rays to treat wet AMD and is
intended as a one-time procedure with the potential to maintain vision while reducing the required number of anti-VEGF injections into the eye. The results
were given at the 14th EURETINA Congress 2014 . Physicians also discussed their clinical experiences treating patients with Oraya Therapy, which
has been rapidly expanding in Europe, with the treatment now available in a total of eight centers across the United Kingdom, Germany and Switzerland.
More information can be found at http://www.businesswire.com/news/home/20140913005002/en/Three-Year-Data-Oraya-Therapeutics’-INTREPID-Study-Continue#.VBh2c66ea79.
|
|
|
|
|
|
| Advertisement |
 |
|
|
|
| Retina Implant AG’s International Clinical Results Presented |
|
|
|
Professor Eberhart Zrenner,
co-founder and lead clinical trial investigator at Retina Implant AG, and founding director of the Institute of Ophthalmic Research, University of Tubingen, Germany, presented the 12-month visual and safety outcomes of 29 patients
blinded by retinitis pigmentosa (RP) who have been implanted with Retina Implant’s Alpha IMS microchip, at the 14th EURETINA Congress 2014. Professor Zrenner said, “Through the data, we conveyed safety of the Alpha IMS as well as evidence suggesting
the device is capable of restoring impactful vision to patients with RP who were blind before implantation.” More information can be found at
http://www.prnewswire.com/news-releases/retina-implant-ags-international-clinical-results-presented-for-the-first-time-in-europe-275090411.html.
|
|
|
|
|
| SalutarisMD Wet AMD Choroidal Distance Study Results Previewed |
|
|
|
Initial results were previewed at the Ophthalmology Futures Forum Europe 2014 from an observational study sponsored by Salutaris Medical Devices, Ltd., conducted at Moorfields Eye Hospital NHS Foundation Trust. The purpose of the study was to accurately measure the scleral and choroid thickness at the fovea and at the choroidal neovascular lesion. SalutarisMD
has a device that employs a minimally invasive retrobulbar episcleral brachytherapy application to the neovascular membranes. Distance from the episcleral
surface to the choroidal lesion is the key to delivering the appropriate prescribed radiation dose and the results of this study will ensure accurate
dosimetry. More information can be found at http://salutarismd.com/salutarismd-wet-amd-choroidal-distance-study-results-previewed-at-ophthalmology-futures-forum-europe-2014/.
|
|
|
|
|
|
| Quantel’s Vitra PDT Laser Granted CE Mark |
|
|
|
Quantel Medical has received CE Mark approval for its Vitra photodynamic therapy laser platform, for the treatment of polypoidal choroidal vasculopathy and central serous retinopathy. Quantel plans to begin
commercializing the laser platform immediately in countries requiring CE registration.
More information can be found at http://www.quantel-medical.com/upload/fichiers/WW1410521081W5412d7f9757520.pdf.
|
|
|
|
|
|
|
|
|
|
|
| Patient Reports Brighter Eyesight Following World’s First iPS Retina Transplant |
|
|
|
A Japanese research team led by the government-backed Riken Institute has performed the world’s first transplant of a retina sheet made of
induced pluripotent stem (iPS) cells, and the patient receiving it says her eyesight is brighter following the procedure. One of the surgeons involved, Yasuo Kurimoto, from the Institute of Biomedical Research and Innovation Hospital in Kobe, Japan said, “The transplant
may have produced the effect, but it is too early to tell.” More information can be found at http://www.japantimes.co.jp/news/2014/09/13/national/patient-claims-brighter-eyesight-worlds-first-ips-retina-transplant/#.VBh6zK6ea78.
|
|
|
|
| |
|
|
|
If you prefer not to receive e-mail from Retinal Physician, please use the following link to remove your e-mail address from this list: Unsubscribe
This message was transmitted by PentaVision | 321 Norristown Road, Suite 150, Ambler, PA 19002 | 215-628-6550
View the PentaVision Privacy Policy | Contact Us - Please do not reply to this e-mail message.
Please make sure our e-mail messages don't get marked as spam by adding visioncareprofessionalemail.com to your "approved senders" list.
|